This review will examine research ethics in the context of globalization of clinical trials and recent rapid developments in bioscience. It will focus on international ethical guidelines and the functions of research ethics review boards in research governance. Consent issues in genetic research, which must comply with privacy laws by protecting confidentiality and privacy of personal health data, will be discussed.
Introduction
The ethics of research are evolving rapidly due to unprecedented developments in biomedical science and the globalization of research in the last decade. It is only 2 years since my review of the ethics of clinical research in anesthesia focused on controversies generated by sponsored clinical trials and conflicts of interest among physician researchers, academic institutions and corporate sponsors. Editors of journals were reviewing publication policies to conform with new privacy laws and the implementation of clinical trials legislation [1] . Now, anesthesiologists are collaborating with basic scientists and government to form interdisciplinary teams of investigators to facilitate the translation of research discoveries into evidence-based clinical practice in the perioperative setting.
Contents of review
This review aims to give anesthesiologists an understanding of research ethics in the context of the global bioscience industry and international environment. Existing ethical guidelines for the conduct of research will be summarized and the first major case of scientific misconduct by a prominent bioscientist will be described. A section is devoted to the governance of anesthesia research and the role of research ethics boards following changes in international regulations. The process of obtaining consent for participation in clinical trials by children and subjects in developing countries is discussed. Finally, concerns about the future of academic anesthesia are identified and the need for anesthesiologists to develop key roles in translational research: to change their role effectively from that of clinician-investigators to physician-scientists.
Ethical guidelines for research
International guidelines have incorporated changing ethical norms to protect human rights since the Nuremberg Code of 1949 made consent from research participants mandatory. The Helsinki Declaration and its revisions, from 1964 to 2000, encouraged scientific advancement as long as a person's health was safeguarded. For the last 25 years, following recommendations in the guidelines of the Council for International Organization of Medical Sciences in 1982, clinical research has been subject to mandatory ethical review. Guidelines were expanded, in 2002, to cover scientific validity, informed consent, vulnerability of individuals, and women as research subjects. The Human Genome Organization in 1998 promoted international collaboration in genetic research, but recognized that consent may not always be needed in the use of anonymized samples and archival materials. The European Union Directive for Good Clinical Practice, published in 2001 [2] , provides a legal framework for the conduct of clinical trials on medicinal products for human use across Europe. Two years after its implementation, however, there is still lack of harmonization in its application to noncommercial research [3 ] .
Contemporary ethical challenges
Contemporary ethical values are challenged in emerging situations created by genetic and biotechnological research, or collaborations between people in developed and developing countries. Interrelationships among researchers, governments, investors, the general public and community groups are complex. Fundamental ethical principles of respect for persons and social justice remain paramount, while cultural and moral differences may have to be accommodated. Common disagreements focus on approval of clinical trials, consent to participation, use of placebos, and standards of medical care.
Universal declaration on bioethics and human rights
Ultimately, decision-making depends on identifying shared ethical values that permit a national and international consensus on ethics in research. The United Nations Educational, Scientific and Cultural Organization (UNESCO) International Bioethics Committee examined bioethical issues related to human dignity, rights and freedoms, in the spirit of cultural pluralism, that relate to scientific experimentation in the international setting. This led to the adoption of the 'Universal Declaration on Bioethics and Human Rights' on 19 October 2005 to set global guidelines for shared ethical values [4 ] . The declaration outlines fundamental ethical principles that should be respected (Table 1) . These principles are laid down to protect future generations, the environment, the biosphere and biodiversity.
Scientific misconduct in the contemporary setting
Honest error and differences in the interpretation of data are not scientific misconduct, which results from 'fabrication, falsification, plagiarism or other practices that seriously deviate from those that are commonly accepted within the scientific community'. Ethical guidelines cannot prevent misconduct, but should help honest scientists to conduct research ethically.
The case of the stem-cell researcher scandal
The scandal of the South Korean scientist, Woo Suk Hwang, who falsely claimed to have cloned human embryos and created patient-specific stem cell lines, has reverberated in the scientific community. His publications, in a prestigious scientific journal in 2005, were acclaimed as the most important advance ever made in stem cell research, offering prospects of a cure for hereditary diseases and the production of replacement tissues. One of the scientific team in Hwang's laboratory contacted a television program to expose the fraud, saying that junior researchers had been coerced into donating eggs and that there was no scientific evidence to support the findings reported in the articles. Investigators traced the source of stem lines to a hospital laboratory and duplication of photographs confirmed that reportedly distinct cell lines came from the same colony [5 ,6 ] .
Sequelae to the Hwang case
Confirmation of this fraud had far-reaching implications, leading to Hwang's dismissal by Seoul University [7], stock market losses in the biotechnical industry [8], and retraction of articles already published [9 ,10 ]. Recognition of the potential value of the research has stimulated other investigators to try to produce these specific stem lines using different techniques [11 ] . The Hwang case impugned ethics as well as science, disgracing himself, harming colleagues and putting the public at risk. It raises compelling arguments for severe legal sanctions to support enforcement of ethical guidelines.
Oversight of research
National and international ethical guidelines are the norms applied to ethics review of research by research ethics boards (REBs) or, in the US, institutional review boards (IRBs).
Even when researchers claim to have conformed to these policies, adverse events and deaths have been reported during clinical trials, so that granting agencies have made recommendations to improve the methodology and conduct of clinical trials [12 ] . Others have addressed concerns about the validity of placebo-controlled trials [13 ] . Universities are aware of public abhorrence of scientific misconduct and are developing educational materials for their staff, students and collaborators to familiarize them with regulatory requirements and procedures for conducting responsible research [14 ] . The regulation of research in humans, however, depends largely on the REB system and the application of ethical guidelines by these committees is often inconsistent: a protocol that is approved by one REB may be rejected by another [15 ] .
Harmonization of research ethics reviews
Some attempts have been made to standardize ethical decision-making by national and international REBs. The European Clinical Trials Directive, concerned with new drug trials, requires that '. . . the ethics committee comes to the conclusion that the anticipated therapeutic and public health benefits justify the risks . . .', with a time limit of 60 days to make a decision. Implementation in Hungary, Portugal, Sweden and the UK depends on various degrees of political control and centralization, Ethics in research Bevan 131 with different structures for REBs at the local level in each country [16 ] . Increasingly, studies that originated in a developed country are conducted in developing countries. International standards require dual ethics review from a local ethics board in the developing country as well as that from the host institution. When the local infrastructure lacks a formal REB, researchers should demonstrate that the research is ethical by being sensitive to cultural needs, communicating with social groups and involving participants in the protocol development [17 ] .
Oversight of clinical research by ethics review committees
Oversight for the conduct of clinical research devolves on the REB system. One contentious issue is the expectation for monitoring of approved research projects, which may be burdensome for overworked committees. Scrutiny of an Australian REB's monitoring practices found that researchers and participants were unsure about the role of the REB and dissatisfied with explanations of the research to subjects [18 ] . Although there are no requirements to provide participants with study 132 Ethics, economics and outcome Table 1 Ethical principles adopted by the Universal Declaration on Bioethics and Human Rights (2005)
Human dignity, human rights and fundamental freedoms
To be fully respected and interests and welfare of individual to have priority over sole interest of science or society 2. Benefit and harm Maximize benefits of research and minimize harm to participants and affected individuals 3. Autonomy and individual responsibility Autonomy of persons to make decisions, while taking responsibility for those decisions, to be respected Take special measures to protect rights and interests of those who cannot make their own decisions 4. Consent Any procedure or research is only to be carried out on a person with the prior, free and informed consent of the person concerned, based on adequate information (exceptions only under international human rights law) Consent may be withdrawn by the person at any time and for any reason without disadvantage or prejudice. For research in communities, need additional agreement of community leaders or legal representatives 5. Persons without the capacity to consent Authorization in accordance with best interest of the person concerned in accordance with domestic law Research only carried out for direct health benefit to person or exceptionally when risk is minimal and research benefit is great Refusal by individual to be respected 6. Respect for human vulnerability and personal integrity Individuals and groups of special vulnerability should be protected and personal integrity of such individuals respected 7. Privacy and confidentiality Privacy of individuals and their personal information should be respected Information should not be used or disclosed for purposes other than those for which it was collected or consented to, consistent with international law, particularly international human rights law 8. Equality, justice and equity
The fundamental equality of all humans in dignity and rights to be respected so that they are treated justly and equitably 9. results, it can be argued that it is fundamental to respect for persons. Under the US Common Rule new information that is obtained during the course of a study, that may influence the person's willingness to participate, has to be disclosed. In other countries, including Canada, this is at the discretion of the REB. There is a growing movement towards offering participants a summary of the results on completion of the research. Only one third of REBs in Canadian Universities has a policy to return results to participants, and none is specific about how this should be done [19 ] . There are no validated indicators for REB performance, in terms of regulatory compliance or internal quality assurance procedures, but there are arguments that commercial REBs make just as sound ethical judgments as voluntary academic boards [20] .
Challenges in ethics review of genetic research
Major ethical concerns surround genomic and proteonomic research and the growth of biotechnology and biobanks (collections of identifiable biological samples selected from a particular clinical or biological group). While lawyers and bioethicists debate the ethical, legal and social issues presented by pharmacogenomic research [21] , or the secondary use of human tissues obtained from victims and families in mass disaster investigations [22] , there is little guidance for REBs in this challenging area. Justifiable concerns for REBs, charged with the protection of human subjects, are informed consent, the ramifications of findings to family and community groups, the use of extra samples for future undisclosed research, and unwanted access to biological samples or genetic data by others. One proposal to assist REBs in the assessment of research involving biobanks suggests a coding system to ensure confidentiality of data, with a medical archivist as a manager [23 ] .
Global research ethics initiatives
The developing world stands to gain by improvements in healthcare as a result of genomic research. Every care must be taken to avoid exploitation of subjects who are recruited from developing countries by external sponsors for nontherapeutic genetic research [24] . Advocates of increased globalization recognize the need for regulations to govern research that serve the needs of both the commercial market and the communities involved, acknowledging the 'global public goods characteristics of genomics knowledge and the private goods nature of its application'. The University of Toronto Canadian Program on Genomics and Global Health advocate the formation of a Global Genomics Institute of government, industry and citizens [25 ] . This sort of initiative might encourage developing countries to improve their regulatory processes to meet international standards and increase the protection of their populations [26] .
Consent for research participation
The legal and ethical components of a valid consent for participation in a clinical trial are the same as for clinical treatment, although researchers are held to higher standards for disclosure of risks and benefits of the procedures proposed. Ethical values of beneficence, nonmaleficence, respect for persons and individual autonomy are applied to obtain a person's informed, competent and voluntary consent to participate in research. Cultural differences that exist between ethnic groups, or between developed and developing countries, produce a wide diversity of values that have to be respected. Potential conflicts of interest for the researchers or institutions because of financial or contractual obligations with sponsors should be disclosed in the consent process [27 ] . While fully informed consent is considered to be ideal, it is a standard that may be difficult to achieve.
Consent for research in children
In research in children, consent for their participation may take the form of permission from a parent or guardian, assent of the child or consent from a mature minor. There is considerable discretion for REBs in deciding how the consent process will be applied to children. A retrospective study of 55 REB decisions in 23 states across the US demonstrated the variability in the consent process approved for three standard protocols of randomized, placebo-controlled clinical trials.
Half of the REBs were satisfied with a line for assent on the permission form, while others wanted a separate assent form with the information in simplified language. Documentation of assent from critically ill children on ventilators was obtained in 11 cases and raised the issue of accepting a waiver of assent in some situations [28 ] .
A continuous consent process for research in neonates
Obtaining valid, informed consent for research in newborns is difficult because the infants are sick and parental stress is high. In a randomized controlled trial of total body hypothermia in babies with perinatal asphyxia in the UK a continuous consent process was found to improve the validity of informed consent [29 ] . Parents were given preliminary information about the trial while the infant was assessed. If eligible for the trial, a detailed information leaflet was provided, followed by a discussion with the parents and a request for written consent. During the trial, the neonatologist met the parents and gave them the opportunity to withdraw the infant from the study. Consent validity was satisfactory in 70% of parents at the time of signing the consent form, while others were unable to understand the situation fully. As the trial progressed and more information was offered, they became more understanding.
Consent to use of personal data
Laws to protect personal privacy and confidentiality have been introduced in many countries, with implications for the ways in which data can be used in research. Researchers have to balance the need for scientific and public health research with protection of patient confidentiality [30 ,31] . Potential harm from disclosure of personal data to medical insurers, educational institutions or employers must be minimized and methods for data protection, such as anonymization or coding systems, explained in the consent process. When an 'opt-out' consent process was replaced by an 'opt-in' consent to satisfy privacy laws, researchers found that the recruitment rate dropped and research costs were increased because more potential subjects had to be interviewed [32 ] .
Consent for use of tissue samples
Consent requirements for research on pathological specimens is controversial and in limited circumstances, involving anonymous or coded tissue samples, is not needed. Informed consent is mandatory for use of biological specimens collected during testing of investigational drugs or for the use of medical devices. Arguments favor specific consent for the use of surgically removed tissues and their retention for future studies. A person has no legal ownership, however, over tissue that has been removed from the body and individual rights no longer apply. The likelihood is that the problems identified in these countries are common to most developed countries: a decade of high clinical workload, financial pressures and physician shortages. Pressures from hospital administrators and the public to meet clinical service commitments have led anesthesia departments to limit academic activities without addressing these fundamental issues.
Recommendations to develop physician-scientists in anesthesia
Schwinn and Balser [35 ] have written a thoughtful analysis of the position in the US that describes the extent of underfunding for anesthesia research and the low academic productivity of the specialty. They strongly recommend the development of physician-scientists in anesthesia and call for radical changes to residency and fellowship training programs to encourage basic science for anesthesiologists to obtain doctorates. There is support for this from their own colleagues [37 ] and Pandit is in substantial agreement that a similar course should be taken in the UK [36 ] . Existing programs for clinicianscientists, with limited scientific exposure, have proved unsatisfactory, while dual training for MD-PhD anesthesiologists is a lengthy commitment. New programs in graduate schools have been funded so that PhD students can earn a Masters of Science degree in medicine and a doctorate in one of the basic sciences [38 ] . It will take time for these promising initiatives to show results. Now, anesthesiologists need to create a professional environment in which these physician scientists can be productive.
Is translational research the future?
Anesthesia research has always been allied to basic sciences: physiology, pharmacology and cellular and molecular biology. New drug development and clinical trials have been the major focus of anesthesia research in the past. Increasing complexity of drug innovation, and the globalization of clinical trials, has removed the potential for dependence on this area in the future. Biological science and biotechnology are growing at a phenomenal rate and spreading geographically [39 ] . Anesthesiologists need to adapt to new opportunities in interdisciplinary health research to promote science and meet the needs of industry and government in this environment [40 ] . They are already changing practice in areas such as cardiac anesthesia with outcome research that links postoperative morbidity to preoperative risk factors. Experiences with the severe acute respiratory syndrome (SARS) in Canada have highlighted the collaborative team approach that is vital in dealing with pandemics [41 ]. If anesthesiologists meet the challenge to foster physician-scientists in the discipline, they will be ideally positioned to move into translational research and speed up the application of research into evidence-based clinical practice [42 ].
This future for anesthesia research will move anesthesiologists into the forefront of biomedical research with ethical duties and responsibilities that were not envisioned previously. They will join the globalized bioscience community with moral responsibilities that encompass those of industry and governments across all countries [43 ] . Bioscience companies all over the world have responded to public criticism of corporate governance by implementing ethical policies for their activities in the international setting. They are reducing their focus on profits and meeting their moral obligation to society, especially in developing countries, through benefit sharing with the local communities [44 ] .
Conclusion
Contemporary research ethics are changing to meet the challenges and opportunities of the globalization of clinical trials and genomic and proteonomic research.
Anesthesiologists are uniquely placed to become physician-scientists and undertake translational research to apply to evidence-based perioperative care. Collaborations with scientists, government and the public, nationally and internationally, that this research involves, will be based on an understanding of the complex ethical issues that have been discussed.
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as: of special interest of outstanding interest Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 161-162). The importance of Hwang's article led to rapid acceptance for publication by Science. Despite scrutiny by editors and nine external reviewers, no problems were identified before publication. A limitation of the peer review process is its inability to detect scientific misconduct. A study of REB approved permission, assent and consent forms for three multicenter clinical trials showed that standards varied. Age at which assent was required was 6-15 years, and monetary compensation offered for inconvenience, travel, parking and food varied.
29
Allmark P, Mason S. Improving the quality of consent to randomised controlled trials by using continuous consent and clinician training in the consent process. J Med Ethics 2006; 32:439-443. A continuous consent process proved to improve consent validity in a controlled randomized trial of total body hypothermia in neonates.
30
Davies C, Collins R. Balancing potential risks and benefits of using confidential data. BMJ 2006; 333:349-351. Use of confidential health data is essential in clinical and public health research, but latitude in interpretation of privacy laws results in differing access to this information. REBs assess the risk-benefits of using such data for each proposal to assure that risks of harm are minimized.
